Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
Asciminib showed superior efficacy and a favorable safety profile in patients with newly diagnosed chronic‑phase CML compared with investigator‑selected TKIs and imatinib.
Patients with newly diagnosed chronic myeloid leukemia (CML) need long‑term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, may offer better efficacy and safety and fewer side effects than currently available frontline ATP‑competitive tyrosine kinase inhibitors (TKIs).
A novel, non‑ATP‑competitive TKI with a distinct mechanism may improve outcomes and reduce toxicity in frontline treatment of chronic‑phase CML.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025
- Chronic myeloid leukemia: Current guidelines for diagnosis and management
- Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment‑free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co‑primary endpoint
- Information about Project 4: Chronic myeloid leukemia (CML)
- Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia